CD70 and nonpapillary renal cell carcinoma: A Phase I multicenter trial (COBALT-RCC) of CRISPR-(CTX-130) in fourteen subjects with stage IV CD70 positive ccRCC, from which six presented refractory disease, has led to 8% durable CR (18+ months) and 69.2% SD.